Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW815SF (fluticasone/salmeterol) vs salmeterol in COPD
NCT00269126Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Primary completion
- Aug 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in pre-dose FEV1 at 4 weeks. Started Feb 2005; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00269126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269126.